Shenzhen We-Linking Medical Technology Co., Ltd. (referred to as "We-Linking"), a startup focuses on the research and development of a full chain of medical-grade implanted wireless brain-computer interface technology, recently announced the completion of tens of millions of RMB in angel+ round A financing, led by Gaorong Ventures, with participation from TTM Capital and Beijing Life Science Park Investment, and follow-on investment from existing shareholder CDH Investments. Earlier this year, the company completed tens of millions of RMB in angel round financing. The total amount raised in the two rounds is nearly 100 million RMB, mainly used to promote the research and development of a fully implanted medical-grade brain-computer interface system and the clinical research of implanted neural electrode arrays.

In recent years, brain-machine interfaces are entering a stage of accelerated clinical translation, and implantable brain-machine interface technology has achieved numerous milestone advancements, from brain-controlled robotic arms, voice reconstruction, restoring upper and lower limb control to treating severe depression and other mental illnesses, brain-machine interfaces have already seen many practical applications. Representative international implantable brain-machine interface companies such as Neuralink, Synchron, and Precision Neuroscience have all secured multiple rounds of financing totaling hundreds of millions of dollars in the past two years, and have received FDA approval to conduct IIT or formal clinical trials.

The founding team of We-Linking comes from top international brain-computer interface research institutions, with over twenty years of international research experience in the fields of basic research, engineering practice, and clinical medicine for implanted brain-computer interfaces. The team was the first to propose an implanted brain-computer interface solution based on a high-density flexible electrode array on the surface of the cortex, which can obtain high spatiotemporal precision neural signals by being attached to the surface of the cortex. Currently, We-Linking has basically completed the research and development of the full-stack basic hardware and software system for brain-computer interfaces.

MicroLing Medical High-Density Flexible Microelectrode Array from We-Linking

LILY ZHANG, founder and managing partner of TTM Capital, stated: "The 21st century is known as the century of brain science, with brain imaging, supercomputing, and information communication technology all in a rapid development stage. At the same time, major countries have successively launched brain initiatives, and this top-down promotion along with substantial research funding is expected to accelerate the comprehensive development of brain science. The founding team has over 20 years of research accumulation in the field of brain science and is familiar with the full-chain technology of several key links, including neural interfaces, chips, and decoding algorithms. Their independently developed adhesive brain-machine electrodes balance safety risks and reading/writing accuracy well, and are expected to promote the application development of brain-machine interfaces in the human body."

About XinThera Pharmaceuticals, Inc